Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.

Despite current control efforts, global tuberculosis (TB) incidence is decreasing slowly. New regimens that can shorten treatment hold promise for improving treatment completion and success, but their impact on population-level transmission remains unclear. Earlier models projected that a four-month...

Full description

Bibliographic Details
Main Authors:	Mariam O Fofana, Gwenan M Knight, Gabriela B Gomez, Richard G White, David W Dowdy
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4015982?pdf=render

Similar Items

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
by: Gwenan M Knight, et al.
Published: (2015-01-01)

Drug-resistant tuberculosis: Progress towards shorter and safer regimens
by: Kavitha Saravu, et al.
Published: (2019-01-01)

Shorter antibiotic regimens impact the control efforts in high tuberculosis burden regions of Taiwan
by: Yi-Jun Lin, et al.
Published: (2020-08-01)

Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings
by: Giovanni Sotgiu, et al.
Published: (2017-03-01)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
by: Philipp du Cros, et al.
Published: (2021-02-01)

Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis.
by: Peter J Dodd, et al.
Published: (2013-01-01)

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
by: Mengjie Jiang, et al.
Published: (2022-06-01)

Correction: Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population Incidence of Tuberculosis.
by: Peter J. Dodd, et al.
Published: (2013-01-01)

Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa
by: J-D K Lotz, et al.
Published: (2023-11-01)

Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India
by: Malaisamy Muniyandi, et al.
Published: (2022-10-01)

Nix-TB and ZeNix trials: Paving the way for shorter regimens for drug-resistant tuberculosis
by: Gyanshankar Mishra
Published: (2021-01-01)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
by: Tutik Kusmiati, et al.
Published: (2022-08-01)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
by: Rajendra Prasad, et al.
Published: (2017-01-01)

Systematic review of efficacy and safety of shorter regimens for drug-resistant tuberculosis (DR-TB) in children
by: Lovely Jain, et al.
Published: (2024-05-01)

Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
by: Yishak Abraham, et al.
Published: (2024-10-01)

No antimicrobial resistance research agenda without tuberculosis
by: Gwenan M Knight, et al.
Published: (2020-08-01)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020
by: Teona Avaliani, et al.
Published: (2021-01-01)

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan
by: Stefan Kohler, et al.
Published: (2022-03-01)

High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam
by: Le T. N. Anh, et al.
Published: (2020-03-01)

Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients
by: Oki Nugraha Putra, et al.
Published: (2024-12-01)

Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study
by: Daniel Legese Achalu, et al.
Published: (2024-08-01)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
by: Abdul Wahid, et al.
Published: (2022-09-01)

Population-level impact of active tuberculosis case finding in an Asian megacity.
by: David W Dowdy, et al.
Published: (2013-01-01)

Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study
by: Achalu DL, et al.
Published: (2023-11-01)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
by: Stefan Kohler, et al.
Published: (2022-01-01)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan.
by: Stefan Kohler, et al.
Published: (2022-01-01)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
by: Souleymane Hassane-Harouna, et al.
Published: (2020-01-01)

Effectiveness of the shorter MDR regimen in the management of tuberculosis: Shortfall in the outcome of disease a multidimensional approach and evaluation for a better alternative
by: Prasanta Kumar Das, et al.
Published: (2020-01-01)

Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection
by: Pei-Jean I. Feng, et al.
Published: (2023-12-01)

Fine with five? Shorter antibiotic courses for childhood meningitis.
by: Snape, MD, et al.
Published: (2011)

Regular Versus Shorter Orientation
by: Carla Abreu-Ellis, et al.
Published: (2008-09-01)

The cockatoos : shorter novels and stories
by: White, Patrick, author
Published: (1978)

Correction: The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan.
by: Stefan Kohler, et al.
Published: (2024-01-01)

Correction: The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
Published: (2024-01-01)

Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens
by: Tutik Kusmiati, et al.
Published: (2022-01-01)

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.
by: Emily A Kendall, et al.
Published: (2017-01-01)

Treatment efficacy of all-oral shorter MDR-TB regimens in the Vladimir region of Russia
by: Anastasiya Gaida, et al.
Published: (2025-03-01)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
by: Pravin K. Singh, et al.
Published: (2019-09-01)

Shorter antitubercular therapy for extrapulmonary tuberculosis - a case report
by: Diviya Bharathi Ravikumar, et al.
Published: (2024-01-01)

Population-level impact of same-day microscopy and Xpert MTB/RIF for tuberculosis diagnosis in Africa.
by: David W Dowdy, et al.
Published: (2013-01-01)